Paul C Lambert

List of Publications by Year
in descending order

155	12,504	53751 45	26591 107
papers	citations	h-index	g-index

158	158	158	18232
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine, 2004, 23, 1351-1375.	0.8	1,376
2	Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ: British Medical Journal, 2010, 340, c221-c221.	2.4	1,256
3	Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ: British Medical Journal, 2007, 334, 299.	2.4	930
4	Progress in cancer survival, mortality, and incidence in seven high-income countries 1995â€“2014 (ICBP) Tj ETQq0 0 0 rgBT /Overlock 10	5.1	634
5	Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. Journal of Clinical Oncology, 2016, 34, 2851-2857.	0.8	625
6	Further Development of Flexible Parametric Models for Survival Analysis. The Stata Journal, 2009, 9, 265-290.	0.9	590
7	How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Statistics in Medicine, 2005, 24, 2401-2428.	0.8	407
8	Changes in the Risk of Death After HIV Seroconversion Compared With Mortality in the General Population. JAMA - Journal of the American Medical Association, 2008, 300, 51.	3.8	404
9	Oral Prednisolone for Preschool Children with Acute Virus-Induced Wheezing. New England Journal of Medicine, 2009, 360, 329-338.	13.9	296
10	Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ: British Medical Journal, 2008, 336, 1180-1185.	2.4	239
11	Metaâ€analysis of continuous outcomes combining individual patient data and aggregate data. Statistics in Medicine, 2008, 27, 1870-1893.	0.8	222
12	Flexible parametric models for relative survival, with application in coronary heart disease. Statistics in Medicine, 2007, 26, 5486-5498.	0.8	202
13	Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics, 2007, 8, 576-594.	0.9	201
14	Efficacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1â€“5 years: randomised controlled trial. Lancet, The, 2003, 362, 1433-1438.	6.3	193
15	Bivariate random-effects meta-analysis and the estimation of between-study correlation. BMC Medical Research Methodology, 2007, 7, 3.	1.4	184
16	A Systematic Review of Molecular and Biological Tumor Markers in Neuroblastoma. Clinical Cancer Research, 2004, 10, 4-12.	3.2	179
17	Survival and cure of acute myeloid leukaemia in <scp>E</scp>ngland, 1971â€2006: a populationâ€based study. British Journal of Haematology, 2013, 162, 509-516.	1.2	177
18	Meta-analysis of heterogeneously reported trials assessing change from baseline. Statistics in Medicine, 2005, 24, 3823-3844.	0.8	173

#	Article	IF	Citations
19	Screening and cervical cancer cure: population based cohort study. BMJ: British Medical Journal, 2012, 344, e900-e900.	2.4	153
20	Evidence-based sample size calculations based upon updated meta-analysis. Statistics in Medicine, 2007, 26, 2479-2500.	0.8	123
21	Choosing the relative survival method for cancer survival estimation. European Journal of Cancer, 2011, 47, 2202-2210.	1.3	120
22	Estimating the loss in expectation of life due to cancer using flexible parametric survival models. Statistics in Medicine, 2013, 32, 5286-5300.	0.8	113
23	Meta-analysis of rare and adverse event data. Expert Review of Pharmacoeconomics and Outcomes Research, 2002, 2, 367-379.	0.7	107
24	Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study. Journal of Clinical Oncology, 2015, 33, 2288-2295.	0.8	106
25	Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models. BMC Medical Research Methodology, 2011, 11, 96.	1.4	98
26	Simulating biologically plausible complex survival data. Statistics in Medicine, 2013, 32, 4118-4134.	0.8	97
27	Estimating the crude probability of death due to cancer and other causes using relative survival models. Statistics in Medicine, 2010, 29, 885-895.	0.8	96
28	Modeling of the Cure Fraction in Survival Studies. The Stata Journal, 2007, 7, 351-375.	0.9	95
29	Flexible parametric modelling of cause-specific hazards to estimate cumulative incidence functions. BMC Medical Research Methodology, 2013, 13, 13.	1.4	94
30	Parametric multistate survival models: Flexible modelling allowing transitionâ€s specific distributions with application to estimating clinically useful measures of effect differences. Statistics in Medicine, 2017, 36, 4719-4742.	0.8	92
31	Joint Modeling of Longitudinal and Survival Data. The Stata Journal, 2013, 13, 165-184.	0.9	88
32	Automated, ambulatory, or conventional blood pressure measurement in pregnancy: Which is the better predictor of severe hypertension?. American Journal of Obstetrics and Gynecology, 1998, 178, 521-526.	0.7	84
33	Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study. BMC Medical Research Methodology, 2011, 11, 4.	1.4	82
34	The use of restricted cubic splines to approximate complex hazard functions in the analysis of time-to-event data: a simulation study. Journal of Statistical Computation and Simulation, 2015, 85, 777-793.	0.7	80
35	Adjusting Survival Time Estimates to Account for Treatment Switching in Randomized Controlled Trialsâ€"an Economic Evaluation Context. Medical Decision Making, 2014, 34, 387-402.	1.2	72
36	Breast Cancer, Sickness Absence, Income and Marital Status. A Study on Life Situation 1 Year Prior Diagnosis Compared to 3 and 5 Years after Diagnosis. PLoS ONE, 2011, 6, e18040.	1.1	68

#	Article	IF	Citations
37	A population-based comparison of the survival of patients with colorectal cancer in England, Norway and Sweden between 1996 and 2004. Gut, 2011, 60, 1087-1093.	6.1	68
38	Individual patient data meta-analysis of survival data using Poisson regression models. BMC Medical Research Methodology, 2012, 12, 34.	1.4	66
39	A general framework for parametric survival analysis. Statistics in Medicine, 2014, 33, 5280-5297.	0.8	64
40	Comparison of methods for calculating relative survival in population-based studies. Cancer Epidemiology, 2012, 36, 16-21.	0.8	62
41	Additive and multiplicative covariate regression models for relative survival incorporating fractional polynomials for time-dependent effects. Statistics in Medicine, 2005, 24, 3871-3885.	0.8	60
42	Comparison of different approaches to estimating age standardized net survival. BMC Medical Research Methodology, 2015, 15, 64.	1.4	57
43	Flexible parametric joint modelling of longitudinal and survival data. Statistics in Medicine, 2012, 31, 4456-4471.	0.8	56
44	A Bayesian approach to evaluating net clinical benefit allowed for parameter uncertainty. Journal of Clinical Epidemiology, 2005, 58, 26-40.	2.4	49
45	Bayesian implementation of a genetic model-free approach to the meta-analysis of genetic association studies. Statistics in Medicine, 2005, 24, 3845-3861.	0.8	48
46	Relative survival: what can cardiovascular disease learn from cancer?. European Heart Journal, 2008, 29, 941-947.	1.0	48
47	Trends in cancer survival in the Nordic countries 1990â€“2016: the NORDCAN survival studies. Acta OncolÃ³gica, 2020, 59, 1266-1274.	0.8	46
48	Urine Protein Estimation in Hypertensive Pregnancy: Which Thresholds and Laboratory Assay Best Predict Clinical Outcome?. Hypertension in Pregnancy, 2005, 24, 291-302.	0.5	43
49	Colorectal cancer survival in socioeconomic groups in England: Variation is mainly in the short term after diagnosis. European Journal of Cancer, 2012, 48, 46-53.	1.3	43
50	The role of observer error in antenatal dipstick proteinuria analysis. BJOG: an International Journal of Obstetrics and Gynaecology, 1999, 106, 1177-1180.	1.1	42
51	Temporal trends in the proportion cured for cancer of the colon and rectum: A population-based study using data from the Finnish Cancer Registry. International Journal of Cancer, 2007, 121, 2052-2059.	2.3	42
52	Estimating the impact of a cancer diagnosis on life expectancy by socio-economic group for a range of cancer types in England. British Journal of Cancer, 2017, 117, 1419-1426.	2.9	41
53	Birth weight and 24-hour ambulatory blood pressure in nonproteinuric hypertensive pregnancy. American Journal of Obstetrics and Gynecology, 2000, 183, 633-637.	0.7	40
54	A Bayesian approach to Markov modelling in cost-effectiveness analyses: application to taxane use in advanced breast cancer. Journal of the Royal Statistical Society Series A: Statistics in Society, 2003, 166, 389-405.	0.6	40

#	Article	IF	Citations
55	Sensitivity analyses allowed more appropriate and reliable meta-analysis conclusions for multiple outcomes when missing data was present. Journal of Clinical Epidemiology, 2004, 57, 911-924.	2.4	40
56	Transmission of Neurodegenerative Disorders Through Blood Transfusion. Annals of Internal Medicine, 2016, 165, 316.	2.0	40
57	Predicting costs over time using Bayesian Markov chain Monte Carlo methods: an application to early inflammatory polyarthritis. Health Economics (United Kingdom), 2007, 16, 37-56.	0.8	39
58	How can we make cancer survival statistics more useful for patients and clinicians: An illustration using localized prostate cancer in Sweden. Cancer Causes and Control, 2013, 24, 505-515.	0.8	39
59	Understanding the impact of socioeconomic differences in colorectal cancer survival: potential gain in life-years. British Journal of Cancer, 2019, 120, 1052-1058.	2.9	37
60	Quantifying differences in breast cancer survival between England and Norway. Cancer Epidemiology, 2011, 35, 526-533.	0.8	36
61	Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study. Statistical Methods in Medical Research, 2018, 27, 765-784.	0.7	35
62	Flexible parametric modelling of the causeâ€specific cumulative incidence function. Statistics in Medicine, 2017, 36, 1429-1446.	0.8	34
63	Minimum sample size calculations for external validation of a clinical prediction model with a timeâ€toâ€event outcome. Statistics in Medicine, 2022, 41, 1280-1295.	0.8	34
64	Cost-Effectiveness Analysis Using Data from Multinational Trials: The Use of Bivariate Hierarchical Modeling. Medical Decision Making, 2007, 27, 471-490.	1.2	33
65	Randomised controlled trial of the effectiveness of feedback in improving test ordering in general practice. Scandinavian Journal of Primary Health Care, 2003, 21, 219-223.	0.6	31
66	Robustness of individual and marginal model-based estimates: A sensitivity analysis of flexible parametric models. Cancer Epidemiology, 2019, 58, 17-24.	0.8	31
67	EFFECT OF CONCENTRATION AND BIOCHEMICAL ASSAY ON THE ACCURACY OF URINE DIPSTICKS IN HYPERTENSIVE PREGNANCIES. Hypertension in Pregnancy, 2001, 20, 205-217.	0.5	30
68	Proportion cured models applied to 23 cancer sites in Norway. International Journal of Cancer, 2013, 132, 1700-1710.	2.3	29
69	A Flexible Parametric Competing-risks Model Using a Direct Likelihood Approach for the Cause-specific Cumulative Incidence Function. The Stata Journal, 2017, 17, 462-489.	0.9	29
70	stgenreg: AStataPackage for General Parametric Survival Analysis. Journal of Statistical Software, 2013, 53, .	1.8	27
71	A Bayesian Approach to a General Regression Model for ROC Curves. Medical Decision Making, 1998, 18, 436-443.	1.2	26
72	Adjusting for the proportion of cancer deaths in the general population when using relative survival: A sensitivity analysis. Cancer Epidemiology, 2012, 36, 148-152.	0.8	26

#	Article	IF	Citations
73	Temporal recalibration for improving prognostic model development and risk predictions in settings where survival is improving over time. International Journal of Epidemiology, 2020, 49, 1316-1325.	0.9	26
74	Analysis of ambulatory blood pressure monitor data using a hierarchical model incorporating restricted cubic splines and heterogeneous within-subject variances. Statistics in Medicine, 2001, 20, 3789-3805.	0.8	25
75	The impact of under and over-recording of cancer on death certificates in a competing risks analysis: A simulation study. Cancer Epidemiology, 2013, 37, 11-19.	0.8	25
76	The loss in expectation of life after colon cancer: a population-based study. BMC Cancer, 2015, 15, 412.	1.1	25
77	Simulating Complex Survival Data. The Stata Journal, 2012, 12, 674-687.	0.9	24
78	Estimating net survival in populationâ€based cancer studies. International Journal of Cancer, 2013, 133, 519-521.	2.3	24
79	Joint modelling of longitudinal and survival data: incorporating delayed entry and an assessment of model misspecification. Statistics in Medicine, 2016, 35, 1193-1209.	0.8	24
80	Understanding the impact of sex and stage differences on melanoma cancer patient survival: a SEER-based study. British Journal of Cancer, 2021, 124, 671-677.	2.9	23
81	Temporal Trends in Mortality From Diseases of the Circulatory System After Treatment for Hodgkin Lymphoma: A Population-Based Cohort Study in Sweden (1973 to 2006). Journal of Clinical Oncology, 2013, 31, 1435-1441.	0.8	22
82	Automated blood pressure measurement as a predictor of proteinuric pre-eclampsia. BJOG: an International Journal of Obstetrics and Gynaecology, 1997, 104, 559-562.	1.1	21
83	Temporal trends in the proportion cured among adults diagnosed with acute myeloid leukaemia in Sweden 1973â€“2001, a populationâ€based study. British Journal of Haematology, 2010, 148, 918-924.	1.2	20
84	Partitioning of excess mortality in population-based cancer patient survival studies using flexible parametric survival models. BMC Medical Research Methodology, 2012, 12, 86.	1.4	20
85	Adjusting for measurement error in baseline prognostic biomarkers included in a time-to-event analysis: a joint modelling approach. BMC Medical Research Methodology, 2013, 13, 146.	1.4	20
86	Estimating the cure proportion of malignant melanoma, an alternative approach to assess long term survival: A population-based study. Cancer Epidemiology, 2014, 38, 93-99.	0.8	20
87	Estimating the cost-effectiveness of an intervention in a clinical trial when partial cost information is available: a Bayesian approach. Health Economics (United Kingdom), 2008, 17, 67-81.	0.8	19
88	Capturing simple and complex time-dependent effects using flexible parametric survival models: A simulation study. Communications in Statistics Part B: Simulation and Computation, 2021, 50, 3777-3793.	0.6	19
89	Prognostic value of admission blood glucose concentration and diabetes diagnosis on survival after acute myocardial infarction: results from 4702 index cases in routine practice. Clinical Science, 2010, 118, 527-535.	1.8	18
90	Modelling Time to Death or Discharge in Neonatal Care: An Application of Competing Risks. Paediatric and Perinatal Epidemiology, 2013, 27, 426-433.	0.8	18

#	Article	IF	Citations
91	Incidence of non-specific abdominal pain in children during school term: population survey based on discharge diagnoses. BMJ: British Medical Journal, 1999, 318, 1455-1455.	2.4	17
92	Illustration of different modelling assumptions for estimation of loss in expectation of life due to cancer. BMC Medical Research Methodology, 2019, 19, 145.	1.4	17
93	Strcs: A Command for Fitting Flexible Parametric Survival Models on the Log-hazard Scale. The Stata Journal, 2016, 16, 989-1012.	0.9	16
94	Direct likelihood inference on the causeâ€specific cumulative incidence function: A flexible parametric regression modelling approach. Statistics in Medicine, 2018, 37, 82-97.	0.8	16
95	Validation of the DCAÂ® 2000 Microalbumin:Creatinine Ratio Urinanalyzer for Its Use in Pregnancy and Preeclampsia. Hypertension in Pregnancy, 2003, 22, 77-92.	0.5	15
96	Urinary microalbumin/creatinine ratios: reference range in uncomplicated pregnancy. Clinical Science, 2003, 104, 103.	1.8	15
97	Bed Occupancy Rates and Hospital-Acquired Clostridium difficile Infection: A Cohort Study. Infection Control and Hospital Epidemiology, 2013, 34, 1062-1069.	1.0	15
98	Loss in life expectancy and gain in life years as measures of cancer impact. Cancer Epidemiology, 2019, 60, 168-173.	0.8	15
99	Survival trends in patients diagnosed with colon and rectal cancer in the nordic countries 1990â€“2016: The NORDCAN survival studies. European Journal of Cancer, 2022, 172, 76-84.	1.3	15
100	Projecting Cancer Incidence using Age-period-cohort Models Incorporating Restricted Cubic Splines. International Journal of Biostatistics, 2012, 8, 33.	0.4	14
101	The analysis of peak expiratory flow data using a three-level hierarchical model. Statistics in Medicine, 2004, 23, 3821-3839.	0.8	13
102	Providing more up-to-date estimates of patient survival: a comparison of standard survival analysis with period analysis using life-table methods and proportional hazards models. Journal of Clinical Epidemiology, 2004, 57, 14-20.	2.4	13
103	Comment on article by Browne and Draper. Bayesian Analysis, 2006, 1, 543.	1.6	13
104	Flexible Parametric Illness-Death Models. The Stata Journal, 2013, 13, 759-775.	0.9	13
105	Adjusting Expected Mortality Rates Using Information From a Control Population: An Example Using Socioeconomic Status. American Journal of Epidemiology, 2018, 187, 828-836.	1.6	13
106	Contemporarily Treated Patients With Hodgkin Lymphoma Have Childbearing Potential in Line With Matched Comparators. Journal of Clinical Oncology, 2018, 36, 2718-2725.	0.8	13
107	Analysis, power and design of antimicrobial resistance surveillance studies, taking account of inter-centre variation and turnover. Journal of Antimicrobial Chemotherapy, 2008, 62, ii29-ii39.	1.3	12
108	Fitting and Modeling Cure in Population-Based Cancer Studies within the Framework of Flexible Parametric Survival Models. The Stata Journal, 2012, 12, 623-638.	0.9	12

#	Article	IF	Citations
109	A flexible parametric approach to examining spatial variation in relative survival. Statistics in Medicine, 2016, 35, 5448-5463.	0.8	12
110	Association of fractures with the incidence of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 419-425.	1.1	12
111	Exploring the impact of cancer registry completeness on international cancer survival differences: a simulation study. British Journal of Cancer, 2021, 124, 1026-1032.	2.9	12
112	The Application of Cure Models in the Presence of Competing Risks. Epidemiology, 2014, 25, 742-748.	1.2	11
113	Loss in working years after a breast cancer diagnosis. British Journal of Cancer, 2018, 118, 738-743.	2.9	11
114	InterPreT cancer survival: A dynamic web interactive prediction cancer survival tool for health-care professionals and cancer epidemiologists. Cancer Epidemiology, 2018, 56, 46-52.	0.8	10
115	Potential gain in life years for Swedish women with breast cancer if stage and survival differences between education groups could be eliminated â€“ Three what-if scenarios. Breast, 2019, 45, 75-81.	0.9	10
116	Reference-adjusted and standardized all-cause and crude probabilities as an alternative to net survival in population-based cancer studies. International Journal of Epidemiology, 2020, 49, 1614-1623.	0.9	10
117	Marginal measures and causal effects using the relative survival framework. International Journal of Epidemiology, 2020, 49, 619-628.	0.9	10
118	Estimation of age-standardized net survival, even when age-specific data are sparse. Cancer Epidemiology, 2020, 67, 101745.	0.8	10
119	Individual participant data metaâ€analysis for external validation, recalibration, and updating of a flexible parametric prognostic model. Statistics in Medicine, 2021, 40, 3066-3084.	0.8	10
120	stpm2cr: A flexible parametric competing risks model using a direct likelihood approach for the cause-specific cumulative incidence function. The Stata Journal, 2017, 17, 462-489.	0.9	10
121	Familial Coaggregation of Alzheimer's Disease and Parkinson's Disease: Systematic Review and Meta-Analysis. Neuroepidemiology, 2014, 42, 69-80.	1.1	9
122	Impact on survival of modelling increased surgical resection rates in patients with non-small-cell lung cancer and cardiovascular comorbidities: a VICORI study. British Journal of Cancer, 2020, 123, 471-479.	2.9	9
123	Estimating restricted mean survival time and expected life-years lost in the presence of competing risks within flexible parametric survival models. BMC Medical Research Methodology, 2021, 21, 52.	1.4	9
124	The impact of excluding or including Death Certificate Initiated (DCI) cases on estimated cancer survival: A simulation study. Cancer Epidemiology, 2021, 71, 101881.	0.8	9
125	The estimation and modelling of cause-specific cumulative incidence functions using time-dependent weights. The Stata Journal, 2017, 17, 181-207.	0.9	9
126	Conditional crude probabilities of death for English cancer patients. British Journal of Cancer, 2019, 121, 883-889.	2.9	8

#	Article	IF	Citations
127	Urinary microalbumin/creatinine ratios: reference range in uncomplicated pregnancy. Clinical Science, 2003, 104, 103-107.	1.8	7
128	Can different definitions of date of cancer incidence explain observed international variation in cancer survival? An ICBP SURVMARK-2 study. Cancer Epidemiology, 2020, 67, 101759.	0.8	7
129	Data Resource Profile: The Virtual Cardio-Oncology Research Initiative (VICORI) linking national English cancer registration and cardiovascular audits. International Journal of Epidemiology, 2021, , .	0.9	7
130	Understanding disparities in cancer prognosis: An extension of mediation analysis to the relative survival framework. Biometrical Journal, 2021, 63, 341-353.	0.6	7
131	Generating high-fidelity synthetic time-to-event datasets to improve data transparency and accessibility. BMC Medical Research Methodology, 2022, 22, .	1.4	6
132	Where Next for Evidence Synthesis of Prognostic Marker Studies? Improving the Quality and Reporting of Primary Studies to Facilitate Clinically Relevant Evidence-Based Results. , 2007, , 39-58.		5
133	Placental Weight and Breast Cancer Survival in Young Women. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 777-783.	1.1	5
134	A multistate model incorporating estimation of excess hazards and multiple time scales. Statistics in Medicine, 2021, 40, 2139-2154.	0.8	5
135	Case-ascertainment of acute myocardial infarction hospitalizations in cancer patients: a cohort study using English linked electronic health data. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 86-95.	1.8	5
136	Rebuttal to editorial saying cancer survival statistics are misleading. BMJ: British Medical Journal, 2011, 343, d4214-d4214.	2.4	4
137	Reference-Adjusted Loss in Life Expectancy for Population-Based Cancer Patient Survival Comparisonsâ€"with an Application to Colon Cancer in Sweden. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1720-1726.	1.1	4
138	Temporal trends in treatmentâ€related incidence of diseases of the circulatory system among Hodgkin lymphoma patients. International Journal of Cancer, 2019, 145, 1200-1208.	2.3	3
139	Relaxing the assumption of constant transition rates in a multi-state model in hospital epidemiology. BMC Medical Research Methodology, 2021, 21, 16.	1.4	3
140	A way to explore the existence of â€œimmortalsâ€•in cancer registry data â€“ An illustration using data from ICBP SURVMARK-2. Cancer Epidemiology, 2022, 76, 102085.	0.8	3
141	Five ways to improve international comparisons of cancer survival: lessons learned from ICBP SURVMARK-2. British Journal of Cancer, 2022, 126, 1224-1228.	2.9	3
142	Non-parametric estimation of reference adjusted, standardised probabilities of all-cause death and death due to cancer for population group comparisons. BMC Medical Research Methodology, 2022, 22, 2.	1.4	3
143	Assessing the impact of including variation in general population mortality on standard errors of relative survival and loss in life expectancy. BMC Medical Research Methodology, 2022, 22, 130.	1.4	3
144	On the choice of timescale for other cause mortality in a competing risk setting using flexible parametric survival models. Biometrical Journal, 2022, 64, 1161-1177.	0.6	3

#	Article	IF	Citations
145	Direct modelling of age standardized marginal relative survival through incorporation of time-dependent weights. BMC Medical Research Methodology, 2021, 21, 84.	1.4	2
146	Temporal Trends in Chronic Myeloid Leukemia Outcome Using the Loss in Expectation of Life: A Swedish Population-Based Study. Blood, 2015, 126, 2779-2779.	0.6	2
147	Development of a dynamic interactive web tool to enhance understanding of multi-state model analyses: MSMplus. BMC Medical Research Methodology, 2021, 21, 262.	1.4	2
148	Potential bias introduced by not including multiple time-scales in survival analysis: a simulation study. Communications in Statistics Part B: Simulation and Computation, 2024, 53, 993-1006.	0.6	2
149	Comments on â€˜Trying to be precise about vaguenessâ€™ by Stephen Senn, Statistics in Medicine 2007; 26:1417â€“1430. Statistics in Medicine, 2008, 27, 619-622.	0.8	1
150	Reply to D. Pulte et al. Journal of Clinical Oncology, 2017, 35, 696-697.	0.8	1
151	Inverse probability weighting and doubly robust standardization in the relative survival framework. Statistics in Medicine, 2021, 40, 6069-6092.	0.8	1
152	Reply to Letter to the Editor by Remontetet al.. Statistics in Medicine, 2015, 34, 3378-3380.	0.8	0
153	Temporal Trends in the Proportion Cured Among Patients Diagnosed with Acute Myeloid Leukemia in Sweden 1973-2001, a Population-Based Study.. Blood, 2009, 114, 1378-1378.	0.6	0
154	Loss in working years after a breast cancer diagnosis: A population-based study (Sweden).. Journal of Clinical Oncology, 2017, 35, 209-209.	0.8	0
155	Obtaining long-term stage-specific relative survival estimates in the presence of incomplete historical stage information. British Journal of Cancer, 0, , .	2.9	0